Page last updated: 2024-09-05

melagatran and glycine

melagatran has been researched along with glycine in 111 studies

Compound Research Comparison

Studies (melagatran)	Trials (melagatran)	Recent Studies (post-2010) (melagatran)	Studies (glycine)	Trials (glycine)	Recent Studies (post-2010) (glycine)
185	32	19	35,163	756	8,415

Protein Interaction Comparison

Protein	Taxonomy	glycine (IC50)
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	1.4852
Sodium- and chloride-dependent glycine transporter 1	Homo sapiens (human)	106
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	0.3253
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	0.3253
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	0.3253
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	0.3253
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	0.3253
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	0.3253
Sodium- and chloride-dependent glycine transporter 2	Homo sapiens (human)	128

Research

Studies (111)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (6.31)	18.2507
2000's	104 (93.69)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Deinum, J; Elg, M; Gustafsson, D	1
Carlsson, S; Eriksson, BI; Halvarsson, M; Mattsson, C; Risberg, B	1
Antonsson, T; Bylund, R; Deinum, J; Elg, M; Eriksson, U; Gustafsson, D; Gyzander, E; Karlsson, O; Mattsson, C; Nilsson, A; Nilsson, I; Pehrsson, S; Sörensen, H	1
Chen, L; Gustafsson, D; Mattsson, C; Mehta, JL; Nichols, WW; Saldeen, TG	1
Eriksson, M; Larsson, A; Mattsson, C; Saldeen, T	2
Deinum, J; Nilsson, T; Sjöling-Ericksson, A	1
Eriksson, H; Eriksson, UG; Frison, L; Hägg, A; Hansson, PO; Held, P; Holmström, M; Jonsson, T; Lapidus, L; Leijd, B; Säfwenberg, U; Stockelberg, D; Taghavi, A; Thorsén, M	1
Basu, S; Eriksson, M; Eriksson, O; Kiiski, R; Larsson, A; Mattsson, C; Nordgren, A	1
Carlsson, S; Elg, M; Gustafsson, D	2
Abrahamsson, A; Antonsson, T; Bredberg, U; Bylund, R; Carlsson, S; Elg, M; Eriksson, U; Gustafsson, D; Gyzander, E; Hoffmann, K; Någård, S; Nyström, J; Sörensen, H; Ungell, A	1
Heinzl, S	1
Hauptmann, J; Steinmetzer, T; Sturzebecher, J	1
Elg, M; Gustafsson, D; Mikulski, A	1
Fleischer, K; Gulba, DC; Lankes, W	1
Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H	1
Lindahl, TL; Mattsson, C; Menschiek-Lundin, A; Wåhlander, K	1
Abrahamsson, P; Ahnoff, M; Larsson, M; Lindmark, B; Logren, U; Persson, BA; Svennberg, H	1
Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P	1
Fiessinger, JN	1
Marder, VJ	1
Abrahamsson, T; Björkman, JA; Hendriks, D; Leurs, J; Mattsson, C; Nerme, V; Scharpé, S; Schatteman, K	1
Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K	1
Ekdahl, KN; Elgue, G; Korsgren, O; Larsson, R; Nilsson, B; Ozmen, L	1
Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A	1
Lassila, R	1
Fenyvesi, T; Harenberg, J; Jörg, I	1
Fenyvesi, T; Harenberg, J; Jörg, I; Piazolo, L; Zokai, K	1
Fenyvesi, T; Harenberg, J; Joerg, I	1
Eriksson, H; Eriksson, UG; Lapidus, L; Larson, G; Olsson, CG; Thuresson, A; Wåhlander, K	1
Carlsson, S; Elg, M; Mattsson, C	1
Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L	1
Abrahamsson, A; Ahnoff, M; Fakt, C; Larsson, M; Logren, U; Ohrman, I; Persson, BA	1
Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N	1
Frebelius, S; Jansson, K; Linder, R; Swedenborg, J	1
Mattsson, C; Nylander, S	1
Haas, S	2
Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Johansson, LC; Logren, U	1
Clement, B; Lopian, K	1
Björnheden, T; Carlsson, S; Grip, L; Mattsson, C; Scherstén, F; Wahlund, G	1
Hamaad, A; Lip, GY; Tayebjee, MH	1
Bodendiek, I; Bruhn, HD; Lentz, S; Seeger, M	1
Andersson, M; Eriksson, UG; Fager, G; Gustafsson, D; Johansson, LC	1
Eriksson, UG; Homolka, R; Peters, GR; Sarich, TC; Svensson, M; Teng, R; Wollbratt, M	1
Ahnoff, M; Bredberg, U; Eriksson, UG; Frison, L; Gislén, K; Gustafsson, D; Johansson, LC	1
Elg, M; Gustafsson, D	1
Eriksson, BI	1
Eriksson, BI; Eriksson, UG; Frison, L; Gisleskog, PO; Gustafsson, D; Hamrén, B; Karlsson, MO; Mandema, JW; Wählby, U	1
Cullberg, M; Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Frison, L	1
Attman, PO; Eriksson, UG; Fager, G; Frison, L; Johansson, S; Mulec, H; Samuelsson, O	1
Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Frison, L; Wåhlander, K	1
Andersson, TB; Bredberg, E; Eriksson, UG; Eriksson-Lepkowska, M; Frison, L; Johansson, S; Larsson, M; Thuresson, A	1
Boström, SL; Hansson, GF; Kjaer, M; Sarich, TC	1
Adams, TE; Everse, SJ; Mann, KG	1
Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI	1
Eriksson, UG; Grind, M; Svensson, M; Wåhlander, K; Wollbratt, M; Wolzt, M	1
Börjesson, I; Carlsson, S; Elg, M	1
Gustafsson, D	1
Braunwald, E; Giugliano, RP	1
Choi, NH; Kim, BH; Ok, JH; Park, SY	1
Frebelius, S; Grip, L; Linder, R; Swedenborg, J	1
Elalamy, I; Lebrazi, J; Samama, MM	1
Eriksson, UG; Johansson, S; Larson, G; Larsson, M; Ohlsson, L; Wåhlander, K	1
Drouet, L	1
Fenyvesi, T; Harenberg, J; Jörg, I; Weiss, C	2
Eichinger, S; Kyrle, PA; Weltermann, A	1
Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N	1
Kleinschmidt, S; Pindur, G; Ziegeler, S	1
Bijsterveld, NR; Keller, TT; Levi, M	1
Evans, HC; Faulds, D; Perry, CM	1
Falk, E; Hansson, GK; Hemdahl, AL; Thorén, P	1
Cvirn, G; Gallistl, S; Koestenberger, M; Leschnik, B; Muntean, W; Rehak, T; Roschitz, B	1
Al-Mousa, EN; Salam, AM	1
Boström, SL; Dagnelid, E; Hansson, GF; Ulvinge, JC	1
Eikelboom, JW; Hankey, GJ	1
Boström, SL; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Levi, M; Sarich, TC; Svensson, M; Wåhlander, K; Weitz, JI; Wolzt, M	1
Weitz, J	1
Bauersachs, RM	1
Samama, MM	1
Bauersachs, R; Brehme, S; Caspary, L; Creutzig, A; Harenberg, J; Hoffmann, U; Landgraf, H; Schellong, S	1
Agnelli, G; Andersson, M; Cohen, A; Dahl, O; Eriksson, BI; Mouret, P; Panfilov, S; Rosencher, N	1
Dorani, H; Eriksson, UG; Kalies, I; Ohlsson, L; Sarich, TC; Schützer, KM; Wall, U	1
Eriksson, UG; Kessler, E; Sarich, TC; Schützer, KM; Wall, U; Wollbratt, M	1
Brighton, TA	1
Cimminiello, C; Planès, A; Samama, MM	1
Baier, K; Cvirn, G; Gallistl, S; Koestenberger, M; Leschnik, B; Muntean, W	2
Cvirn, G; Gallistl, S; Koestenberger, M; Muntean, W	1
Andersen, JC	1
Boda, Z	1
Petersen, P	1
Eriksson, UG; Hellgren, M; Johansson, S; Wåhlander, K	1
Auboyer, C; Laporte, S; Mismetti, P; Molliex, S; Zufferey, P	1
Carlsson, S; Elg, M	1
Furugohri, T; Honda, Y; Isobe, K; Matsumoto, C; Muramatsu, S; Shiozaki, Y; Sugiyama, N	1
Attman, PO; Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Ottosson, P; Samuelsson, O	1
Nielsen, JD	1
Flanigan, MJ	1
Cvirn, G; Fritsch, P; Gallistl, S; Koestenberger, M; Leschnik, B; Muntean, W	1
Hering, D; Horstkotte, D; Piper, C	1
Eriksson, UG; Sarich, TS; Wolzt, M	2
Cvirn, G; Gallistl, S; Koestenberger, M; Kutschera, J; Muntean, W	1
Bylock, A; Christersson, C; Oldgren, J; Siegbahn, A; Wallentin, L	1
Meyer Samama, M	1
Craven, S; Dewar, L; Greinacher, A; Ofosu, FA; Sheppard, JA; Warkentin, TE	1

Reviews

31 review(s) available for melagatran and glycine

Article	Year
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. Expert opinion on investigational drugs, 2000, Volume: 9, Issue:5 Topics: Animals; Azetidines; Benzylamines; Glycine; Humans; Shock, Septic; Thrombin	2000
Advances in the development of thrombin inhibitors. Expert opinion on investigational drugs, 2001, Volume: 10, Issue:5 Topics: Arginine; Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Hirudin Therapy; Hirudins; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin	2001
[Direct thrombin antagonists]. Herz, 2001, Volume: 26 Suppl 1 Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors	2001
Anticoagulation: the present and future. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2001, Volume: 7, Issue:3 Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis	2001
[Treatment of deep vein thrombosis. Current and future questions]. Bulletin de l'Academie nationale de medecine, 2001, Volume: 185, Issue:8 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Recurrence; Risk Factors; Venous Thrombosis	2001
[Thrombosis in spite of warfarin--what should be done?]. Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:24 Topics: Anticoagulants; Antiphospholipid Syndrome; Azetidines; Benzylamines; Blood Coagulation; Glycine; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Neoplasms; Recurrence; Thrombin; Thrombosis; Treatment Failure; Warfarin	2001
The METHRO trials. Expert opinion on investigational drugs, 2003, Volume: 12, Issue:5 Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Prodrugs; Thrombin; Venous Thrombosis	2003
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thrombosis research, 2003, Jul-15, Volume: 109 Suppl 1 Topics: Azetidines; Benzylamines; Glycine; Hemostasis; Humans; Pharmacokinetics; Prodrugs; Thrombin; Thrombosis	2003
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thrombosis research, 2003, Jul-15, Volume: 109 Suppl 1 Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboembolism; Thrombosis; Treatment Outcome	2003
Medical indications and considerations for future clinical decision making. Thrombosis research, 2003, Jul-15, Volume: 109 Suppl 1 Topics: Azetidines; Benzylamines; Cardiovascular Diseases; Clinical Protocols; Clinical Trials as Topic; Glycine; Humans; Thromboembolism	2003
Oral direct thrombin inhibitors in clinical development. Journal of internal medicine, 2003, Volume: 254, Issue:4 Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; Prodrugs; Pyridines; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K	2003
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents]. Bulletin de l'Academie nationale de medecine, 2003, Volume: 187, Issue:1 Topics: Administration, Oral; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Thrombosis; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Glycine; Hirudin Therapy; Humans; Orthopedics; Polysaccharides; Prodrugs; Prothrombin; Research; Thrombin; Thromboembolism; Time Factors; Venous Thrombosis	2003
Novel anticoagulants for the prevention and treatment of venous thromboembolism. Wiener medizinische Wochenschrift (1946), 2003, Volume: 153, Issue:19-20 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation Factors; Drugs, Investigational; Fondaparinux; Glycine; Heparin; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Pulmonary Embolism; Research; Thrombin; Venous Thrombosis; Vitamin K	2003
[Melagatran and ximelagatran. Pharmacologic characteristics and anesthesiological aspects]. Der Anaesthesist, 2003, Volume: 52, Issue:12 Topics: Anesthesia; Animals; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Half-Life; Humans	2003
Recombinant factor VIIa as an antidote for anticoagulant treatment. Seminars in hematology, 2004, Volume: 41, Issue:1 Suppl 1 Topics: Anticoagulants; Azetidines; Benzylamines; Factor VII; Factor VIIa; Glycine; Helminth Proteins; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins	2004
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs, 2004, Volume: 64, Issue:6 Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Warfarin	2004
The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Glycine; Humans; Prodrugs; Stroke; Thrombin; Thromboembolism; Venous Thrombosis	2004
Orally active direct thrombin inhibitors. Seminars in vascular medicine, 2003, Volume: 3, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Blood Coagulation; Drug Monitoring; Glycine; Humans; International Normalized Ratio; Postoperative Complications; Prodrugs; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K	2003
[Low molecular weight heparin, fondaparinux and melagatran: new data and clinical studies]. Pharmazie in unserer Zeit, 2004, Volume: 33, Issue:3 Topics: Angina, Unstable; Animals; Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Thrombosis	2004
[Prevention and treatment of deep vein thrombosis with ximelagatran]. Deutsche medizinische Wochenschrift (1946), 2004, Jul-23, Volume: 129, Issue:30 Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin; Hirudin Therapy; Humans; Pipecolic Acids; Polysaccharides; Prodrugs; Sulfonamides; Thrombin; Venous Thrombosis	2004
The direct thrombin inhibitor melagatran/ximelagatran. The Medical journal of Australia, 2004, Oct-18, Volume: 181, Issue:8 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Glycine; Humans; Myocardial Infarction; Secondary Prevention; Stroke; Thrombin; Treatment Outcome; Venous Thrombosis	2004
Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Seminars in thrombosis and hemostasis, 2004, Volume: 30, Issue:6 Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Factor Xa Inhibitors; Fondaparinux; Glycine; Heparin; Heparin, Low-Molecular-Weight; Humans; Models, Biological; Orthopedics; Polysaccharides; Postoperative Complications; Thromboembolism; Thrombolytic Therapy	2004
[New anticoagulants in clinical practice]. Orvosi hetilap, 2004, Dec-05, Volume: 145, Issue:49 Topics: Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Humans; Polysaccharides; Protein C; Pulmonary Embolism; Recombinant Proteins; Venous Thrombosis	2004
Ximelagatran--a promising new drug in thromboembolic disorders. Current pharmaceutical design, 2005, Volume: 11, Issue:4 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Randomized Controlled Trials as Topic; Stroke; Thrombin; Thromboembolism; Venous Thrombosis	2005
Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration. Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Humans; Meta-Analysis as Topic; Orthopedics; Random Allocation; Regression Analysis; Risk; Risk Factors; Thrombin; Thromboembolism	2005
[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?]. Ugeskrift for laeger, 2005, May-23, Volume: 167, Issue:21 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Clinical Trials, Phase III as Topic; Fibrinolytic Agents; Fondaparinux; Glycine; Humans; Polysaccharides; Postoperative Complications; Pulmonary Embolism; Thromboembolism; Venous Thrombosis	2005
Melagatran anticoagulation during haemodialysis--'Primum non nocere'. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:9 Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Heparin; Humans; Renal Dialysis; Safety	2005
Drug insight: an overview of current anticoagulation therapy after heart valve replacement. Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:8 Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Thromboembolism; Vitamin K	2005
Pharmacokinetics and pharmacodynamics of ximelagatran. Seminars in vascular medicine, 2005, Volume: 5, Issue:3 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Biological Availability; Glycine; Humans; Thrombin	2005
Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol. Seminars in vascular medicine, 2005, Volume: 5, Issue:3 Topics: Anticoagulants; Azetidines; Benzylamines; Cytochrome P-450 Enzyme System; Drug Interactions; Ethanol; Food; Glycine; Humans	2005
[The new antithrombotic agents]. Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Hirudins; Humans; Injections, Subcutaneous; Platelet Aggregation Inhibitors; Polysaccharides; Prodrugs; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Venous Thrombosis	2005

Trials

27 trial(s) available for melagatran and glycine

Article	Year
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thrombosis and haemostasis, 1999, Volume: 81, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Female; Glycine; Humans; Infusions, Intravenous; Male; Middle Aged; Thrombin; Thrombophlebitis; Treatment Outcome	1999
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Thrombosis and haemostasis, 2002, Volume: 87, Issue:2 Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Female; Glycine; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Postoperative Complications; Prodrugs; Safety; Sweden; Thrombin; Thromboembolism; Treatment Outcome; Venous Thrombosis	2002
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thrombosis and haemostasis, 2002, Volume: 87, Issue:4 Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; DNA Mutational Analysis; Double-Blind Method; Europe; Factor V; Female; Genetic Predisposition to Disease; Genotype; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Promoter Regions, Genetic; Prospective Studies; Prothrombin; Pulmonary Embolism; Risk Factors; Thrombophilia; Venous Thrombosis	2002
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thrombosis research, 2002, Mar-01, Volume: 105, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cyclodextrins; Female; Fibrinolytic Agents; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Phlebography; Thromboembolism; Venous Thrombosis	2002
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thrombosis research, 2002, Aug-15, Volume: 107, Issue:3-4 Topics: Administration, Oral; Adult; Aged; Azetidines; Benzylamines; Female; Fibrinolytic Agents; Glycine; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pharmacokinetics; Prodrugs; Pulmonary Embolism; Thrombin; Treatment Outcome; Venous Thrombosis	2002
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (London, England), 2002, Nov-09, Volume: 360, Issue:9344 Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Prodrugs; Thromboembolism	2002
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thrombosis and haemostasis, 2003, Volume: 89, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Prodrugs; Prospective Studies; Pulmonary Embolism; Safety; Thrombin; Treatment Outcome; Venous Thrombosis	2003
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical pharmacokinetics, 2003, Volume: 42, Issue:4 Topics: Administration, Oral; Adult; Age Factors; Aged; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Cross-Over Studies; Female; Fibrinolytic Agents; Food-Drug Interactions; Glycine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Metabolic Clearance Rate; Middle Aged; Prodrugs; Thrombin	2003
No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clinical pharmacokinetics, 2003, Volume: 42, Issue:5 Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Azetidines; Benzylamines; Black People; Glycine; Humans; Inactivation, Metabolic; Male; Prodrugs; Racial Groups; Thrombin; White People	2003
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clinical pharmacokinetics, 2003, Volume: 42, Issue:5 Topics: Administration, Oral; Adult; Area Under Curve; Azetidines; Benzylamines; Female; Glycine; Half-Life; Humans; Inactivation, Metabolic; Male; Obesity; Thrombin	2003
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. European journal of clinical pharmacology, 2003, Volume: 59, Issue:1 Topics: Administration, Oral; Adult; Analysis of Variance; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Food-Drug Interactions; Glycine; Half-Life; Humans; Male; Metabolic Clearance Rate; Partial Thromboplastin Time; Prodrugs; Prothrombin Time; Thrombin	2003
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thrombosis research, 2003, Jul-15, Volume: 109 Suppl 1 Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboembolism; Thrombosis; Treatment Outcome	2003
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clinical pharmacokinetics, 2003, Volume: 42, Issue:7 Topics: Administration, Cutaneous; Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Biological Availability; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Glycine; Humans; Metabolic Clearance Rate; Partial Thromboplastin Time; Postoperative Complications; Sweden; Thromboembolism; Venous Thrombosis; Whole Blood Coagulation Time	2003
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. European journal of clinical pharmacology, 2003, Volume: 59, Issue:4 Topics: Administration, Oral; Adult; Aspirin; Azetidines; Benzylamines; Blood Coagulation; Cross-Over Studies; Double-Blind Method; Drug Interactions; Glycine; Humans; Infusions, Intravenous; Male; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Prodrugs; Thrombin; Whole Blood Coagulation Time	2003
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clinical pharmacokinetics, 2003, Volume: 42, Issue:8 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Glycine; Half-Life; Humans; Injections, Subcutaneous; International Normalized Ratio; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Thrombin; Time Factors	2003
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical pharmacokinetics, 2003, Volume: 42, Issue:8 Topics: Administration, Oral; Adult; Aged; Amidines; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Glycine; Half-Life; Humans; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Prothrombin Time; Thrombin	2003
Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clinical pharmacokinetics, 2003, Volume: 42, Issue:8 Topics: Administration, Oral; Adult; Aged; Amidines; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diazepam; Diclofenac; Drug Interactions; Glycine; Humans; In Vitro Techniques; Infusions, Intravenous; Microsomes, Liver; Middle Aged; Nifedipine; Nordazepam; Prodrugs; Thrombin	2003
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:5 Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Factor Xa Inhibitors; Glycine; Humans; Inhibitory Concentration 50; Injections, Subcutaneous; Male; Reference Values; Thrombin; Time Factors; Veins	2003
Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. European journal of clinical pharmacology, 2003, Volume: 59, Issue:7 Topics: Administration, Oral; Adult; Aged; Aging; Area Under Curve; Atrial Fibrillation; Azetidines; Benzylamines; Female; Glycine; Humans; Infusions, Intravenous; Male; Middle Aged; Thrombin	2003
Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:7 Topics: Adult; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Glycine; Half-Life; Hemorrhage; Humans; Injections, Subcutaneous; Male; Pharmacokinetics; Thrombin	2003
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Male; Middle Aged; Preoperative Care; Therapeutic Equivalency; Thrombin; Thromboembolism; Venous Thrombosis	2003
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and haemostasis, 2004, Volume: 91, Issue:6 Topics: Adult; Azetidines; Benzylamines; Biomarkers; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Interactions; Factor VII; Factor VIIa; Glycine; Humans; Male; Platelet Activation; Recombinant Proteins; Single-Blind Method; Thrombosis; Time Factors	2004
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin. Thrombosis and haemostasis, 2004, Volume: 92, Issue:2 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Blood Transfusion; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Logistic Models; Odds Ratio; Time Factors	2004
No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. Journal of clinical pharmacology, 2004, Volume: 44, Issue:8 Topics: Administration, Oral; Adult; Anticholesteremic Agents; Anticoagulants; Area Under Curve; Atorvastatin; Azetidines; Benzylamines; Cross-Over Studies; Drug Combinations; Drug Interactions; Female; Glycine; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Partial Thromboplastin Time; Prodrugs; Pyrroles	2004
No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. Journal of clinical pharmacology, 2004, Volume: 44, Issue:8 Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Digoxin; Double-Blind Method; Drug Interactions; Female; Glycine; Half-Life; Humans; Male; Partial Thromboplastin Time; Prodrugs	2004
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:9 Topics: Adult; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Chronic Disease; Dalteparin; Glycine; Humans; International Normalized Ratio; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Uremia	2005
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:10 Topics: Aged; Azetidines; Benzylamines; Biomarkers; Blood Coagulation; Dose-Response Relationship, Drug; Female; Fibrin; Glycine; Humans; Male; Myocardial Infarction; Partial Thromboplastin Time; Pharmacokinetics; Thrombin; Time Factors	2005

Other Studies

54 other study(ies) available for melagatran and glycine

Article	Year
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thrombosis and haemostasis, 1997, Volume: 78, Issue:4 Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time	1997
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thrombosis and haemostasis, 1997, Volume: 78, Issue:5 Topics: Animals; Azetidines; Benzylamines; Dalteparin; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Infusions, Intravenous; Injections, Intravenous; Male; Piperidines; Rats; Rats, Wistar; Thrombin; Thrombophlebitis; Vena Cava, Inferior	1997
Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thrombosis and haemostasis, 1998, Volume: 79, Issue:1 Topics: Administration, Oral; Animals; Azetidines; Benzylamines; Binding, Competitive; Biological Availability; Dogs; Fibrinolytic Agents; Glycine; Hemodynamics; Male; Mice; Mice, Inbred Strains; Molecular Structure; Molecular Weight; Platelet Aggregation Inhibitors; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Serine Proteinase Inhibitors; Thrombin	1998
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. Journal of cardiovascular pharmacology, 1998, Volume: 31, Issue:3 Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Azetidines; Benzylamines; Coronary Thrombosis; Dogs; Electric Stimulation; Fibrinogen; Fibrinolytic Agents; Glycine; Microscopy, Electron, Scanning; Partial Thromboplastin Time; Thrombin	1998
Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thrombosis and haemostasis, 1998, Volume: 80, Issue:6 Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Creatinine; Diuresis; Drug Evaluation, Preclinical; Endotoxemia; Female; Fibrinolytic Agents; Glycine; Half-Life; Hemodynamics; Kidney; Male; Oxygen Consumption; Partial Thromboplastin Time; Platelet Count; Shock, Septic; Swine; Thrombin	1998
The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. Journal of enzyme inhibition, 1998, Volume: 13, Issue:1 Topics: Antithrombins; Area Under Curve; Arginine; Azetidines; Benzylamines; Binding Sites; Dipeptides; Fluorescence; Glycine; Humans; Kinetics; Molecular Weight; Pipecolic Acids; Piperidines; Spectrometry, Fluorescence; Spectrophotometry; Sulfonamides; Thrombin	1998
Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs. Acta anaesthesiologica Scandinavica, 2000, Volume: 44, Issue:1 Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Endotoxemia; Female; Fibrin; Glycine; Hemodynamics; Liver; Male; Platelet Count; Swine; Tumor Necrosis Factor-alpha	2000
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thrombosis research, 2001, Feb-01, Volume: 101, Issue:3 Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation; Blood Coagulation Factors; Drug Interactions; Factor VII; Factor VIIa; Glycine; Male; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Thrombosis	2001
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thrombosis research, 2001, Feb-01, Volume: 101, Issue:3 Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation Factors; Factor IX; Factor VIIa; Factor VIII; Glycine; Hemorrhage; Humans; Rabbits; Rats; Thrombin; von Willebrand Factor	2001
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thrombosis research, 2001, Feb-01, Volume: 101, Issue:3 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Caco-2 Cells; Glycine; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Prodrugs; Thrombin	2001
[New thrombolytic agents]. Medizinische Monatsschrift fur Pharmazeuten, 2001, Volume: 24, Issue:2 Topics: Anticoagulants; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin; Humans; Thrombosis; Venous Thrombosis	2001
The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thrombosis research, 2001, Mar-15, Volume: 101, Issue:6 Topics: Administration, Oral; Animals; Antithrombins; Azetidines; Benzylamines; Brain Infarction; Cerebral Cortex; Drug Evaluation, Preclinical; Glycine; Hypertension; Injections, Intravenous; Light; Male; Photochemistry; Piperidines; Rats; Rats, Inbred SHR	2001
Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thrombosis and haemostasis, 2001, Volume: 86, Issue:2 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Glycine; Humans; Indicators and Reagents; Inhibitory Concentration 50; International Normalized Ratio; Prothrombin Time; Sensitivity and Specificity; Thromboplastin	2001
Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Jan-05, Volume: 766, Issue:1 Topics: Azetidines; Benzylamines; Chromatography, Liquid; Fibrinolytic Agents; Glycine; Humans; Mass Spectrometry; Reference Standards; Sensitivity and Specificity	2002
Maximized hemostasis. Thrombosis and haemostasis, 2002, Volume: 87, Issue:4 Topics: Animals; Azetidines; Benzylamines; Carboxypeptidase B2; Fibrinolysis; Glycine; Hemostasis; Humans; Mice; Mice, Knockout; Thrombin; Thrombolytic Therapy; Thromboplastin	2002
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thrombosis and haemostasis, 2002, Volume: 87, Issue:4 Topics: Animals; Aorta; Azetidines; Benzylamines; Carboxypeptidase B2; Coronary Circulation; Coronary Thrombosis; Dogs; Enzyme Activation; Enzyme Precursors; Female; Fibrinolytic Agents; Glycine; Male; Models, Animal; Random Allocation; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Veins	2002
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes, 2002, Volume: 51, Issue:6 Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Blood Platelets; Cadaver; CD11 Antigens; Female; Fibrin; Glycine; Humans; Immunohistochemistry; Inflammation; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Middle Aged; Neutrophils; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thrombosis	2002
Monitoring of anticoagulant effects of direct thrombin inhibitors. Seminars in thrombosis and hemostasis, 2002, Volume: 28, Issue:4 Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation Tests; Drug Monitoring; Glycine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sensitivity and Specificity; Sulfonamides; Thrombin	2002
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model. Seminars in thrombosis and hemostasis, 2002, Volume: 28, Issue:4 Topics: Antithrombin III; Azetidines; Benzylamines; Fibrin; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Hirudins; Humans; Models, Cardiovascular; Peptide Hydrolases; Platelet Activation; Platelet Factor 4; Thrombin; Thrombosis	2002
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. Clinical chemistry, 2002, Volume: 48, Issue:10 Topics: Administration, Oral; Anticoagulants; Arginine; Azetidines; Benzylamines; Drug Synergism; Glycine; Hirudins; Humans; Phenprocoumon; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides	2002
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. Thrombosis research, 2002, Aug-15, Volume: 107, Issue:3-4 Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hirudins; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Thrombosis; Venae Cavae	2002
Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Jan-15, Volume: 783, Issue:2 Topics: Animals; Antithrombins; Azetidines; Benzylamines; Chromatography, Liquid; Glycine; Humans; Mice; Milk, Human; Rats; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization	2003
Melagatran. Exanta, H 319/68. Drugs in R&D, 2002, Volume: 3, Issue:6 Topics: Animals; Azetidines; Benzylamines; Dogs; Fibrinolytic Agents; Glycine; Humans; Mice; Thrombosis	2002
Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:2 Topics: Antithrombins; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Endothelium, Vascular; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Piperidines; Protein C; Thrombin; Thrombomodulin	2003
Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:2 Topics: Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Male; P-Selectin; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Receptor, PAR-1; Receptors, Thrombin; Statistics as Topic; Thrombin	2003
[New anticoagulants -- their clinical significance]. Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Biological Availability; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Glycine; Humans; Meta-Analysis as Topic; Polysaccharides; Prodrugs; Risk Factors; Stroke; Thrombosis	2003
[The first oral thrombin inhibitor. Competition to heparins and marcumar?]. MMW Fortschritte der Medizin, 2003, Mar-06, Volume: 145, Issue:10 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Glycine; Humans; Phenprocoumon; Placebos; Prodrugs; Thrombin; Thromboembolism; Thrombosis; Time Factors	2003
Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug metabolism and disposition: the biological fate of chemicals, 2003, Volume: 31, Issue:5 Topics: Administration, Oral; Amidines; Animals; Azetidines; Benzylamines; Chromatography, High Pressure Liquid; Esters; Glycine; Humans; Hydrolysis; In Vitro Techniques; Kidney; Liver; Microsomes; Mitochondria, Liver; Prodrugs; Swine; Thrombin	2003
Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:3 Topics: Angioplasty, Balloon, Coronary; Animals; Azetidines; Benzylamines; Blood Platelets; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fibrin; Fibrinolytic Agents; Glycine; Male; Models, Animal; Platelet Adhesiveness; Radioactive Tracers; Swine; Thrombosis	2003
[Chromogenic substrate as antidote against the thrombin inhibitor Melagatran?]. Hamostaseologie, 2003, Volume: 23, Issue:2 Topics: Antidotes; Antithrombins; Azetidines; Benzylamines; Chromogenic Compounds; Glycine; Humans; Oligopeptides	2003
Predicting the pharmacology of thrombin inhibitors. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:5 Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Computer Simulation; Dose-Response Relationship, Drug; Glycine; Hirudins; Humans; Kinetics; Models, Cardiovascular; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin	2003
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:3 Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Glycine; Hemorrhage; Hirudin Therapy; Hirudins; Male; Rabbits; Risk Assessment; Thrombin; Thrombosis	2003
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat. Biopharmaceutics & drug disposition, 2003, Volume: 24, Issue:6 Topics: Animals; Antithrombins; Azetidines; Benzylamines; Chemistry, Pharmaceutical; Constriction, Pathologic; Cyclodextrins; Delayed-Action Preparations; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelium, Vascular; Glycine; Injections, Subcutaneous; Male; Partial Thromboplastin Time; Pharmaceutical Vehicles; Poloxamer; Rats; Rats, Sprague-Dawley; Solutions; Sweden; Thrombin Time; Vena Cava, Inferior; Venous Thrombosis	2003
Improving antithrombotic treatment in patients after myocardial infarction. Lancet (London, England), 2003, Sep-06, Volume: 362, Issue:9386 Topics: Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome; Warfarin	2003
Determination of melagatran in rabbit plasma by high-performance liquid chromatography with automated column switching. Biomedical chromatography : BMC, 2003, Volume: 17, Issue:6 Topics: Animals; Automation; Azetidines; Benzylamines; Calibration; Chromatography, High Pressure Liquid; Glycine; Rabbits; Reproducibility of Results	2003
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin. Thrombosis research, 2003, Jun-01, Volume: 110, Issue:4 Topics: Amino Acid Chloromethyl Ketones; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Coagulants; Coronary Artery Disease; Fibrinopeptide A; Glycine; Hirudins; Humans; Peptide Fragments; Piperidines; Protein C; Thrombin	2003
In vitro effect of melagatran and lepirudin on clot-bound thrombin. Thrombosis research, 2003, Jun-01, Volume: 110, Issue:4 Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinant Proteins; Thrombin; Thrombosis	2003
Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thrombosis research, 2003, Volume: 111, Issue:1-2 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Blood Coagulation Tests; Fibrinolytic Agents; Glycine; Hirudins; Humans; Kinetics; Outpatients; Phenprocoumon; Recombinant Proteins; Reference Values	2003
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice. American journal of physiology. Heart and circulatory physiology, 2004, Volume: 287, Issue:2 Topics: Animals; Apolipoproteins E; Azetidines; Benzylamines; Biomarkers; Coronary Artery Disease; Coronary Thrombosis; Electrocardiography; Glycine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptors, LDL; Thrombin; Troponin T	2004
Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2004, Volume: 15, Issue:2 Topics: Azetidines; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Eptifibatide; Factor Xa; Glycine; Humans; Peptide Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prothrombin; Thrombin; Thromboplastin	2004
Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2004, Volume: 15, Issue:1 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Enzyme Activation; Factor V; Glycine; Humans; Prodrugs; Thrombin	2004
The beginning of the end of warfarin? The Medical journal of Australia, 2004, Jun-07, Volume: 180, Issue:11 Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Glycine; Humans; Platelet Aggregation Inhibitors; Prodrugs; Thrombin; Warfarin	2004
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs]. Journal des maladies vasculaires, 2004, Volume: 29, Issue:2 Topics: Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Thrombin; Thrombosis	2004
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study. Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:11 Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Therapeutic Equivalency; Thromboembolism; Treatment Outcome; Venous Thrombosis	2004
Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination. Thrombosis research, 2005, Volume: 115, Issue:1-2 Topics: Adult; Anticoagulants; Antithrombin III; Azetidines; Benzylamines; Blood; Blood Coagulation; Dose-Response Relationship, Drug; Fetal Blood; Glycine; Humans; Infant, Newborn; Peptide Fragments; Peptide Hydrolases; Prothrombin; Thrombin	2005
Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2004, Volume: 15, Issue:8 Topics: Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Fibrinolytic Agents; Glycine; Heparin; Humans; Partial Thromboplastin Time; Peptide Fragments; Protein C; Prothrombin; Prothrombin Time; Recombinant Proteins	2004
Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation. Journal of thrombosis and thrombolysis, 2004, Volume: 18, Issue:1 Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Drug Combinations; Glycine; Heparin; Humans; Protein C; Prothrombin Time; Recombinant Proteins	2004
The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation. BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:5 Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Breast Feeding; Female; Glycine; Humans; Lactation; Milk, Human; Postpartum Period; Puerperal Disorders; Thrombin; Thromboembolism; Venous Thrombosis	2005
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2005, Volume: 16, Issue:4 Topics: Animals; Azetidines; Benzylamines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hemorrhage; Male; Rats; Rats, Sprague-Dawley; Venae Cavae; Venous Thrombosis; Warfarin	2005
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. European journal of pharmacology, 2005, May-02, Volume: 514, Issue:1 Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Glycine; Male; Naphthalenes; Propionates; Rats; Rats, Wistar; Thrombin; Thromboplastin; Thrombosis	2005
Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Thrombosis and haemostasis, 2005, Volume: 94, Issue:1 Topics: Anticoagulants; Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Fetal Blood; Glycine; Heparin; Humans; Infant, Newborn; Protein C; Prothrombin Time; Recombinant Proteins; Thrombin; Thromboplastin; Umbilical Veins	2005
Comparison of two different ecarin clotting time methods. Journal of thrombosis and thrombolysis, 2005, Volume: 20, Issue:1 Topics: Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Endopeptidases; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinant Proteins; Viper Venoms	2005
Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma. Acta paediatrica (Oslo, Norway : 1992), 2005, Volume: 94, Issue:7 Topics: Adult; Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Fetal Blood; Glycine; Heparin; Humans; Partial Thromboplastin Time; Protein C; Prothrombin Time; Recombinant Proteins	2005
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and haemostasis, 2005, Volume: 94, Issue:5 Topics: Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Cattle; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Glycine; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Species Specificity; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin	2005